Health AI Central
Share:
Peer-Reviewed Publication
J Dermatolog Treat2026;37(1):2709917.December 1, 2026Journal Article

Response to letter to the editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Emma Guttman-Yassky1, Thomas Bieber2,3, Kenji Kabashima4,5,6, Jan Gutermuth7, Stephan Weidinger8, Andreas Wollenberg9,10,11, Irina Lazariciu12, Gerardo Encinas13, Marina Mikheil14, Melissa Watkins15
1Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, USA.
2Department of Dermatology and Allergy, Ludwig-Maximilian University Hospital of Munich, Munich, Germany.
3Christine Kühne-Center for Allergy Research and Education, Medicine Campus Davos, Davos, Switzerland.
4Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
5Agency for Science, Technology, and Research (A*STAR), Skin Research Labs, Skin Research Institute of Singapore, Singapore.
6Singapore Immunology Network, A*STAR, Singapore.
7Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.
8Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
9Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany.
10Comprehensive Center for Inflammatory Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
11Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.
12IQVIA, Kirkland, QC, Canada.
13Pfizer SA de CV, Mexico City, Mexico.
14Pfizer Inc, Collegeville, PA, USA.
15Pfizer Inc, New York, NY, USA.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.